GPCR vs. BBIO, OGN, IONS, CYTK, APLS, MDGL, ALPN, NUVL, ALKS, and PRGO
Should you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include BridgeBio Pharma (BBIO), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Structure Therapeutics (NASDAQ:GPCR) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations, community ranking and risk.
Structure Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -246.24%. BridgeBio Pharma's return on equity of 0.00% beat Structure Therapeutics' return on equity.
91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 9.4% of Structure Therapeutics shares are held by company insiders. Comparatively, 24.7% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
BridgeBio Pharma received 128 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Structure Therapeutics an outperform vote while only 68.25% of users gave BridgeBio Pharma an outperform vote.
Structure Therapeutics presently has a consensus price target of $83.13, suggesting a potential upside of 143.06%. BridgeBio Pharma has a consensus price target of $47.62, suggesting a potential upside of 69.99%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than BridgeBio Pharma.
Structure Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Structure Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, BridgeBio Pharma had 10 more articles in the media than Structure Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 8 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.91 beat BridgeBio Pharma's score of 0.44 indicating that Structure Therapeutics is being referred to more favorably in the media.
Summary
BridgeBio Pharma beats Structure Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Structure Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Structure Therapeutics Competitors List
Related Companies and Tools
